Literature DB >> 26013691

Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains.

Michael Schmidt1, Michael K Hourfar1, Walid Sireis1, Ulrich Pfeiffer1, Stephan Göttig2, Volkhard A J Kempf2, Carl P McDonald3, Erhard Seifried1.   

Abstract

BACKGROUND: To increase blood safety, various procedures are currently implemented, including donor selection, optimized donor arm disinfection, and diversion. In addition, pathogen inactivation (PI) techniques can be used for platelets (PLTs) and plasma concentrates. STUDY DESIGN AND METHODS: This study investigated the clinical efficacy of an inactivation technique for different blood components at two time points (12 and 35.5 hr). Eight transfusion-relevant bacterial strains were spiked at two different concentrations (100 and 1000 colony-forming units [CFUs]/bag) into whole blood (WB), apheresis PLTs (APs), and buffy coat (BC)-derived minipool PLTs.
RESULTS: The bacterial concentrations were higher than 10(6) CFUs/mL within 24 hours after spiking depending on the particular bacterial strain. PI was absolute for all of the APs performed 12 hours after inoculation, but the bacterial strains of Klebsiella pneumoniae and Bacillus cereus were not completely inactivated in WB or BC PLTs, performed 35.5 and 12 hours after inoculation, respectively.
CONCLUSION: The INTERCEPT PI system was not 100% effective for high concentrations of certain K. pneumoniae strains or spore-forming B. cereus. A critical observation was that the period between blood donation and inactivation needs to be minimal to enable efficient PI. In the case where PI cannot be performed immediately after preparation, a combination of a PI technology after the production of blood components with a rapid bacterial screen test on Day 4 or 5 after donation may offer a solution to further prevent the risk of bacterial transmission by transfusion.
© 2015 AABB.

Entities:  

Mesh:

Year:  2015        PMID: 26013691     DOI: 10.1111/trf.13171

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  14 in total

1.  Financial impact of alternative approaches to reduce bacterial contamination of platelet transfusions.

Authors:  Seema Kacker; Evan M Bloch; Paul M Ness; Eric A Gehrie; Christi E Marshall; Parvez M Lokhandwala; Aaron A R Tobian
Journal:  Transfusion       Date:  2019-01-08       Impact factor: 3.157

Review 2.  Microbiological Screening of Platelet Concentrates in Europe.

Authors:  Marcel Prax; Isabelle Bekeredjian-Ding; Oleg Krut
Journal:  Transfus Med Hemother       Date:  2019-03-20       Impact factor: 3.747

3.  Hemostatic efficacy of pathogen-reduced platelets in children undergoing cardiopulmonary bypass.

Authors:  Sophia Hsien; Jeffrey D Dayton; Dennis Chen; Arabella Stock; Emile Bacha; Melissa M Cushing; Marianne E Nellis
Journal:  Transfusion       Date:  2021-12-13       Impact factor: 3.157

Review 4.  Recent Advances in Preventing Adverse Reactions to Transfusion.

Authors:  Thomas S Rogers; Mark K Fung; Sarah K Harm
Journal:  F1000Res       Date:  2015-12-17

5.  Fatal Sepsis Associated with Bacterial Contamination of Platelets - Utah and California, August 2017.

Authors:  Roberta Z Horth; Jefferson M Jones; Janice J Kim; Bert K Lopansri; Sarah J Ilstrup; Joy Fridey; Walter E Kelley; Susan L Stramer; Ashok Nambiar; Lynn Ramirez-Avila; Amy Nichols; Wendy Garcia; Kelly F Oakeson; Nicholas Vlachos; Gillian McAllister; Robert Hunter; Allyn K Nakashima; Sridhar V Basavaraju
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-06-29       Impact factor: 17.586

Review 6.  History and Future of Nucleic Acid Amplification Technology Blood Donor Testing.

Authors:  Willi Kurt Roth
Journal:  Transfus Med Hemother       Date:  2019-02-05       Impact factor: 3.747

7.  Transfusion of pathogen-reduced platelet components without leukoreduction.

Authors:  Joycelyn Sim; Wai Chiu Tsoi; Cheuk Kwong Lee; Rock Leung; Clarence C K Lam; Claudia Koontz; Amy Yingjie Liu; Norman Huang; Richard J Benjamin; Hans J Vermeij; Adonis Stassinopoulos; Laurence Corash; Albert K W Lie
Journal:  Transfusion       Date:  2019-03-28       Impact factor: 3.157

8.  Non-ionizing 405 nm Light as a Potential Bactericidal Technology for Platelet Safety: Evaluation of in vitro Bacterial Inactivation and in vivo Platelet Recovery in Severe Combined Immunodeficient Mice.

Authors:  Michelle Maclean; Monique P Gelderman; Sandhya Kulkarni; Rachael M Tomb; Caitlin F Stewart; John G Anderson; Scott J MacGregor; Chintamani D Atreya
Journal:  Front Med (Lausanne)       Date:  2020-01-15

9.  Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.

Authors:  Frédéric Garban; Audrey Guyard; Helene Labussière; Claude-Eric Bulabois; Tony Marchand; Christiane Mounier; Denis Caillot; Jacques-Olivier Bay; Valérie Coiteux; Aline Schmidt-Tanguy; Catherine Le Niger; Christine Robin; Patrick Ladaique; Simona Lapusan; Eric Deconinck; Carole Rolland; Alison M Foote; Anne François; Chantal Jacquot; René Tardivel; Pierre Tiberghien; Jean-Luc Bosson
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

Review 10.  Platelet Transfusion-Insights from Current Practice to Future Development.

Authors:  Annina Capraru; Katarzyna Aleksandra Jalowiec; Cesare Medri; Michael Daskalakis; Sacha Sergio Zeerleder; Behrouz Mansouri Taleghani
Journal:  J Clin Med       Date:  2021-05-06       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.